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Abstract
Canine babesiosis is a significant tick-borne disease caused by various species of the protozoan genus Babesia. Although
it occurs worldwide, data relating to European infections have now been collected for many years. These data have
boosted the publication record and increased our working knowledge of these protozoan parasites. Both the large and
small forms of Babesia species (B. canis, B. vogeli, B. gibsoni, and B. microti-like isolates also referred to as "B. vulpes" and
"Theileria annae") infect dogs in Europe, and their geographical distribution, transmission, clinical signs, treatment, and
prognosis vary widely for each species. The goal of this review is to provide veterinary practitioners with practical
guidelines for the diagnosis, treatment and prevention of babesiosis in European dogs. Our hope is that these
guidelines will answer the most frequently asked questions posed by veterinary practitioners.
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Background
Towards the end of the 19th Century, Dr. Victor Babes, a
Romanian physician, observed microorganisms in the
erythrocytes of cattle and sheep with haemoglobinuria.
These microorganisms were later named Babesia bovis and
Babesia ovis, respectively, with the genus name Babesia
after its discoverer [1]. Not long after these observations in
ruminants came the first description of Babesia spp. infec-
tion in dogs, in Italy (1895) [2]. Currently, these protozoan
diseases occur worldwide [3, 4].
Parasites of this genus are primarily transmitted through
tick bites and as such can infect a wide variety of domestic
and wild animals as well as humans [5]. This association
arose as a byproduct of the tick’s adaptation to feed on
blood. Not surprisingly, dogs are one of Babesia spp.
many targets, with various species of Babesia infecting
canines and causing canine babesiosis (formerly called
canine piroplasmosis). Hard ticks are the main vectors for
Babesia spp.; within the tick, Babesia spp. undergo the
sexual conjugation and the sporogony portions of their
life-cycles. These stages occur within the intestinal lumen
and then within the haemocoel of the tick. A blood meal
will ultimately transmit the sporozoites from the tick’s
salivary gland to their new vertebrate host, whereupon the
protozoan life-cycle is completed by asexual replication
(merogony) within the red blood cells, where the parasites
appear as merozoites.
This guide to babesiosis in dogs focuses on Europe and
is aimed towards informing veterinarians working in small
animal practices. This document is intended to answer the
most commonly asked questions about the clinical man-
agement, including diagnosis, treatment, prognosis and
prevention of these parasitic diseases, with an emphasis
on the European context.
Review
Which species of Babesia can infect dogs in Europe?
Traditionally, the morphology of the protozoan (piroplasm
merozoites) within the red blood cell was used as the chief
taxonomic determinant. This assessment, made by micro-
scopic evaluation of a blood smear, can be used to classify
these protozoa as either large (e.g. Babesia canis) or small
forms (e.g. Babesia gibsoni). Subsequently, molecular tech-
niques allowed the identification of several species of Babe-
sia that can infect dogs.
The large Babesia spp., previously considered to be B.
canis, currently include B. canis, Babesia rossi and Babe-
sia vogeli as distinct species [6]. Their identical morph-
ology initially led B. rossi and B. vogeli to be thought of
as subspecies of B. canis, although significant differences
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in their clinical presentation, geographical distribution
and vector specificity now lead us to consider otherwise
[4, 7–10]. In addition, a large-form Babesia species, re-
lated to Babesia bigemina, has been described in North
Carolina in the United States [11].
Thus far, only three small Babesia species with clinical
importance have been described: B. gibsoni, Babesia
conradae [12, 13], and the recently reported "Babesia
vulpes" [14] suggested by Baneth et al. [14] for the pre-
viously named Babesia "Spanish dog isolate", Babesia
"microti-like", "Babesia (Theileria) annae", and Babesia
cf. microti [15, 16], based on their natural hosts and on
an apparent lack of any pre-erythrocytic stage of infec-
tion in lymphocytes. However, no types were fixed for
both, "Theileria annae" and “Babesia vulpes"; therefore,
these names must be considered nomina nuda and thus
unavailable names.
In this review, we will use Babesia microti-like sp. to
describe this infection. Interestingly, a Theileria spp. in-
fection phylogenetically closely related to Theileria spp.
found in sable has been reported in South Africa as a
cause of disease with bleeding tendency associated with
severe thrombocytopenia and anaemia in dogs [17, 18].
Logically, the geographical distribution of Babesia spp.
depends on the presence of competent ticks to transmit
each of them; thus far, not all such species have been
identified in Europe. For the large Babesia species, only
B. canis and B. vogeli have been found in Europe; a single
record of detection of DNA of B. rossi needs confirmation
[19]. As far as small Babesia species are concerned, B.
microti-like sp. and B. gibsoni have been reported in
several European countries [4] (Table 1).
In addition, molecular studies reported Theileria equi,
Theileria annulata and Babesia caballi infections de-
tected only by polymerase chain reaction (PCR) in dogs
from Spain [20], Croatia [21] and France [19]. Theileria
equi infections have also been documented in Jordan
[22], Nigeria [23] and South Africa [17]. However, the
epidemiological and clinical significance of these infec-
tions in dogs remain unknown.
What are the vectors and the geographical distributions
of Babesia spp. causing disease in dogs in Europe?
For B. canis, the relevant vector is the tick Dermacentor
reticulatus. This tick species has a relatively wide range
across Europe, preferring cool and wet climates [24]. While
particularly abundant in large areas of central Europe, it
can be found even in isolated pockets from Portugal to
Poland [25]. The association of this tick species with the
transmission of B. canis has been documented in both field
and laboratory studies [26–28], principally those conducted
in France and Germany. The adult tick parasitises dogs
while immature individuals feed on wild rodents and are
endophilous. Adult ticks are most active during the winter
months, with increased activity from October to March, if
the winter is not too severe. Favourite habitats are the
verges of paths that run through open fields or pastures
near forests; a preference for sparse, vegetated, and sunny
patches explains the tick’s affinity for paths [29].
Some experimental data have shown that the brown dog
tick, Rhipicephalus sanguineus (s.l.) (hereinafter R. sangui-
neus), transmits Babesia species (e.g. B. vogeli) that infect
dogs [7, 28]. Rhipicephalus sanguineus is abundant in
Mediterranean areas, preferring temperate climates, but
being endophilous can also tolerate colder regions of cen-
tral Europe and the British Isles [30]. The importation of
tick-infested dogs from Mediterranean regions may be a
common feature for cases detected in these colder climes
[30]. As yet, there are no complete data for the geograph-
ical distribution of the brown dog tick, because unfortu-
nately, no consensus exists regarding its morphological
identification [31]. The ability of this tick to survive in-
doors also complicates any precise determination of its
restrictive range in the wild [32]. We do, however, know
that hibernation (for example, in the crevices of kennel
buildings) is induced as temperatures dip below 6 °C.
Table 1 Geographical distribution, relevant vectors, and the expected size of Babesia spp. in blood smears. Data for the primary
Babesia species found in Europe provided
Species Geographical distribution Vector Approximate size (μm)
in a blood smear
Reference
Babesia canis Described across most of Europe (from Portugal
to the north and east of Europe), and especially
common in cool and wet climates. Higher
prevalence in central Europe and lower prevalence
in the Mediterranean basin
Dermacentor reticulatus 2.5 × 4.5 [9, 21, 55, 56, 58, 61,
84, 100, 149–151]
Babesia vogeli Albania, Croatia, France, Greece, Italy, Portugal,
Romania, Serbia, Slovenia, Spain and Turkey
Rhipicephalus sanguineus 2.5 × 4.5 [9, 21, 55, 56, 58, 61,
62, 84, 100, 149–151]
Babesia gibsoni Croatia, Germany, Italy, Serbia, Slovakia, Spain
and United Kingdom
Rhipicephalus sanguineus?a 1 × 3 [21, 48, 73, 152–154]
Babesia microti-like
sp.
Croatia, France, Italy, Portugal, Serbia, Spain
and Sweden
Ixodes hexagonusaIxodes
canisugaa
1 × 2.5 [21, 35, 50, 62, 63]
aVectorial ability has not been demonstrated in the laboratory; its role is an assumption based on epidemiological data
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There is also a requirement for some humidity, which can
be provided artificially around buildings by ornamental
water features and other artificial irrigation. Not surpris-
ingly, mild and humid riverbanks, with their increased
density of wild carnivores, are also popular areas of adult
tick infestation, which peaks between May and August.
The largely unnoticed larvae (hatched from tick eggs)
will appear on their hosts in the summer, with the last
developmental stage completing in August - September.
The hibernating stage is either the engorged nymph or
the newly molted adult [32]. Ticks of the complex R.
sanguineus may serve as potential vectors for B. gibsoni,
at least in Europe, while in Asia, its main distribution
range is attributed to transmission by the tick Haema-
physalis longicornis [33, 34].
Details of the life-cycle of B. microti-like sp. are still
largely unknown, but the species Ixodes hexagonus has
been implicated as the potential tick vector, given their
discovery on dogs infected with the protozoan [35, 36].
Ixodes hexagonus exclusively develops the "pholeophilic"
(burrow-dwelling) cycle, so-called by the French re-
searchers who reported this activity [37, 38]. Ixodes hexago-
nus is entirely absent from vegetation, and its free-living
stages are confined to the den, where it commonly parasit-
ises hedgehogs and wild carnivores such as foxes. Conse-
quently, this tick favours areas shared with a high density
of these wild carnivores and is commonly found on hunt-
ing dogs or dogs that investigate burrows, including aban-
doned ones. Ixodes hexagonus, together with a related
species, I. canisuga, is present in practically all areas where
foxes are abundant [39], including where B. microti-like sp.
is yet to be described, which leaves some ambiguity regard-
ing transmission. However, B. microti-like sp. DNA has
been identified in both I. hexagonus and I. ricinus [40], as
well as in I. canisuga [41], although no data exist to sub-
stantiate their competence as vectors for B. microti-like sp.
An official map displaying the known distribution of
D. reticulatus can be found at http://ecdc.europa.eu/en/
healthtopics/vectors/vector-maps/Pages/VBORNET-maps-
tick-species.aspx. The European distribution of R. sangui-
neus has already been published [32] and updated [42].
The distribution of the other tick species acting as vectors
of Babesia spp. to dogs is still too fragmentary to be
mapped.
Are there other modes of transmission for these
infections in dogs?
Although protozoans of the genus Babesia undergo part of
their life-cycles in the tick vector, the merozoites circulating
in the blood may be transmitted to a healthy host directly
by blood transfusion. This scenario has been described for
B. gibsoni infection [43], which can also be transmitted ver-
tically [44] and by direct contact between dogs through
wounds (fighting dogs), saliva or blood ingestion [45–47].
Interestingly, most dogs reported with B. gibsoni infection
in the United States, Australia, and Europe have been Pit
Bull Terriers, a result of their fighting behaviour [45–48].
The first clinical evidence of possible vertical transmission
has also been now documented for B. canis [49] and B.
microti-like sp. [50].
What are the geographical distribution and prevalence of
Babesia spp. infections in dogs in Europe?
The geographical distribution of Babesia spp. infections in
Europe is highly variable (Fig. 1) and largely dependent on
the distribution of the competent tick vector. In addition,
the prevalence of Babesia spp. infections in Europe varies
(Table 2), likely because of the various diagnostic tech-
niques used for detection, the country and population
analysed, and the species of Babesia under investigation.
Table 2 shows the prevalence of Babesia spp. infections in
dogs across Europe. Regarding large Babesia species, B.
canis has been diagnosed in various northern European
countries, as well as in central and southern Europe
[4, 51]. Babesia canis is ordinarily considered to be an
infection of central Europe, principally because of the
abundance of its main vector, D. reticulatus, in that region
[52]. Results from a questionnaire-based study in France
[53] indicated that the annual rate of overall incidence of
B. canis infection seen in veterinary clinics was approxi-
mately 1 %, although some regions reported a higher inci-
dence of up to 16 % [53]. Interestingly, three strains of B.
canis, based on polymorphisms of the Bc28.1-gene, have
been reported in Europe, with a large variation in their
geographical distribution [54]. Babesia vogeli has been
found in Turkey, Albania, Slovenia, Romania, Italy, France,
Spain and Portugal [4, 55, 56]. The prevalence described
for B. canis, using molecular methods, ranges from 2.3 %
in Italy [57] to 4.6 % in Slovenia [58], 25.3 % in Poland
[59], and up to 44.8 % in Romania [60]. With regard to B.
vogeli, although the number of studies is still low, preva-
lence is described as ranging from 0.9 % in France [61] to
1.3 % in Slovenia [58].
Concerning the small Babesia species, B. microti-like
sp. isolates have been detected in dogs in Croatia [21],
Serbia [62], Sweden [63], France [64], and especially in
the Iberian Peninsula, specifically northern Portugal [50]
and Galicia (Spain) [16, 35, 65]. Babesia microti-like sp.
isolates have been detected in red foxes from Spain [66],
Portugal [67], Italy [68], Croatia [69], Germany [41], Austria
[70], Hungary [71] and Bosnia and Herzegovina [72]. Clin-
ical cases associated with infection by B. gibsoni have also
been described in Germany [73], Croatia [21], Italy [48],
Serbia [51] and Spain [74, 75]. Unfortunately, we still lack
detailed geographical distribution and prevalence data for
the small-sized Babesia species because most descriptions
are based on individual clinical case reports. However, for
Croatia, molecular data have revealed a prevalence of 0.7 %
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for B. gibsoni and 0.1 % for B. microti-like sp. [21]. There-
fore, epidemiological data of prevalence of clinical illness or
subclinical infection is more limited for small Babesia spe-
cies in Europe.
What is the public health importance of Babesia
infections?
None of the Babesia species that affect dogs and/or cats
are considered to be of zoonotic importance [76]. More-
over, there is a lack of evidence that Babesia spp. known
to be zoonotic actually have the capacity to infect dogs.
However, the data for addressing this topic are incom-
plete given that some cases of human babesiosis are re-
ported without any firm identification of the causative
protozoan species [77].
Human babesiosis is a rare disease and primarily in-
volves just two species of Babesia: Babesia divergens, a
parasite of cattle in Europe, and Babesia microti that
parasitises small rodents in the United States [76]. Vari-
ants of these two zoonotic species in Europe include a B.
divergens-like species, Babesia sp. EU1 (also called B.
venatorum) and a B. microti-like species, which is only
sporadically reported [78].
Infection by B. divergens, following transmission by I.
ricinus, can result in severe clinical disease, especially in
immunocompromised patients (undergoing chemother-
apy, splenectomised, or human immunodeficiency virus-
positive). In immunocompetent individuals, it presents
as a mild or subclinical infection [78].
Is there a breed, age or sex predisposition for canine
babesiosis?
A breed predisposition has been suggested in Hungary,
citing the vulnerability of the German Shepherd and
Komondor breeds to developing babesiosis due to B. canis
[79]. Predisposition of other breeds for B. canis [80], B.
vogeli [81], B. gibsoni [45] and B. rossi [82] infections has
been described in different latitudes.
Regarding the sex preference, intact females have a
lower risk of presenting babesiosis due to B. rossi when
compared with intact or neutered males and neutered
females. The reason for this predisposition has not been
fully elucidated [82], but it has been suggested that tes-
tosterone causes prolonged and more intense B. microti
parasitemia in infected male rodents [83].
Young dogs are more likely to present severe babesiosis
when infected by B. canis, B. vogeli [4, 84] or B. rossi
[85]. Similarly, old hunting dogs infected by B. microti-
like sp. are reported to have a greater risk for develop-
ing azotemia [86].
What clinical signs and laboratory abnormalities are
found in dogs infected with Babesia spp.?
The clinical manifestations found during the course of
Babesia spp. infections vary, ranging from subclinical in-
fections to multi-organ failure, with a risk of death [87].
While the spectrum of disease may appear daunting, the
collection of an extensive history and clinical presenta-
tion data backed by laboratory abnormalities should
allow the veterinarian to shorten the list of differential
Fig. 1 The distribution of canine Babesia species in Europe in dogs based mainly on molecular analysis. Note the presence of B. canis and B. microti-like
sp. mostly in the cooler climate zones of north and central Europe while infection with B. vogeli is mainly around the Mediterranean basin. The references
for each country are included in the reference list. Figure updated from Solano-Gallego & Baneth [4]
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diagnoses [4]. The history and common and diverse clin-
ical signs and laboratory abnormalities observed among
the Babesia species, the course of several types of Babe-
sia infection, and prognoses are shown in Table 3.
The wide range of clinical manifestations depends
very much on the species of Babesia causing infection
and other factors that affect the severity of the disease,
including age, splenectomy, immune competence, and
concomitant infection or disease [4, 10]. In addition,
disease severity has been associated with parasite density
in B. rossi infection [88]. However, limited information is
available regarding disease severity and parasite density in
other Babesia species. In a recent study, parasite density
was not different between survivors and non-survivors in
dogs infected with B. canis [89]. It is likely that different
Babesia spp. might result in different parasitemias due to
Table 2 Prevalence of canine infection by Babesia spp. in Europe
Species Country Prevalence in % (population studied) Technique employed Reference
Babesia canis Slovenia 4.6 (238) PCR [58]
Spaina 1.3 (153) PCR [155]
Spaina 10 (120) PCR [35]
Italya 20.7 (164) PCR [84]
Italy 2.3 (420) PCR [57]
Italyb 70 (249) IFAT [156]
Polandb 25.3 (82) PCR [59]
Croatia 2.3 (848) PCR [21]
Romania 44.8 (216) PCR [60]
Romaniaa 71.4 (49) PCR [153]
Slovakiac 3.5 (366) PCR [157]
Lithuaniaa 87.8 (123) PCR [158]
Turkey 0.1 (757) PCR [159]
France 12.9 (140) PCR [64]
Bulgaria 16.2 (167) ELISA [160]
Babesia vogeli Slovenia 1.3 (238) PCR [58]
Italya 6.7 (164) PCR [84]
Italya 4 (99) PCR [93]
Croatia 0.2 (848) PCR [21]
Serbia 1.9 (158) PCR [62]
Spaina 2 (153) PCR [155]
France 0.9 (108) PCR [61]
France 13.6 (140) PCR [64]
Babesia gibsonid Croatia 0.7 (848) PCR [21]
Serbia 5.7 (158) PCR [62]
Spaina 2 (153) PCR [155]
Spaina 2.5 (120) PCR [35]
Romaniaa 28.6 (49) PCR [153]
Babesia microti-like sp. Spaina 1.9 (2,979) Microscopy and PCR [161]
Spaina 62.5 (120) Microscopy and PCR [35]
Spaina 0.7 (153) PCR [155]
Croatia 0.1 (848) PCR [21]
France 0.7 (140) PCR [64]
Serbia 10.1 (158) PCR [62]
aStudy conducted using dogs with a suspected infection, transmitted by ticks/babesiosis
bStudy conducted using shelter dogs
cStudy conducted in Dirofilaria-infected dogs
dPrevalence studies performed in Europe are rare, although clinical cases have been described at various locations
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differences in disease severity, but further studies need to
confirm this hypothesis.
Differences in virulence have been described among
Babesia species infecting dogs. In general, it is assumed
that the least pathogenic large-sized species of Babesia
is B. vogeli, at least for adult dogs, and that the most
virulent species is B. rossi, which is probably found only
in Africa. The pathogenicity of small-sized Babesia spp.,
such as B. gibsoni and B. microti-like sp., is moderate to
severe [4, 10, 90].
There are clinical signs and clinicopathological abnor-
malities that are common across all Babesia species infect-
ing dogs (Table 3). Frequent clinical signs associated with
canine babesiosis are apathy, weakness, anorexia, pale mu-
cous membranes and a poor general condition. All Babesia
species can cause fever, enlarged lymph nodes and spleen,
anaemia, thrombocytopenia, jaundice and pigmenturia. Al-
though thrombocytopenia, to a varying extent, is frequently
detected, the presence of petechiae or ecchymosis is less
common. Thrombocytopenia, when present, varies from
mild to severe, as does anaemia. Other abnormalities that
can be detected include hypoalbuminemia and hyperbiliru-
binemia [4, 10]. Depending on the infective species and the
course of infection, anaemia can be regenerative; nonre-
generative anaemia is more typically associated with B.
canis [84]. In all species, anaemia is caused by a combin-
ation of intravascular and extravascular hemolysis resulting
from parasite-caused injury and rupture of red blood cells,
the cells’ increased osmotic fragility, and the activity of sec-
ondary immune-mediated processes.
Some clinical signs and clinicopathological abnormal-
ities differ among Babesia species infecting dogs (Table 3).
Many dogs could present other clinical signs that are
not directly related to hemolysis by piroplasms but that
demonstrate the involvement of other organs. These
complications are especially prevalent following infec-
tion by B. rossi. A non-exhaustive list includes weight loss,
acute or chronic nephropathy, glomerulonephritis, coagu-
lation disorders (disseminated intravascular coagulation),
jaundice from liver disease, immune-mediated hemolysis
or thrombocytopenia, hemoconcentration, shock, meta-
bolic and/or respiratory alkalosis, and/or acidosis, gastro-
intestinal disorders (vomiting or diarrhea), pancreatitis,
ascites, ocular lesions (uveitis or blindness), myalgia,
rhabdomyolysis and respiratory problems (edema or acute
respiratory distress) [91].
It must be noted that many “carrier” dogs with chronic
infections will not present with any clinical signs as
the result of premunition or concomitant immunity
unless their health deteriorates, for example from im-
munosuppressive treatment, splenectomy, or any other
immune-compromised situation (e.g. post-surgical stress
or debilitating disease). This phenomenon has been de-
scribed in Greyhounds infected by B. vogeli and in Pit Bull
Terriers infected by B. gibsoni [45, 92]. It results from the
inability of the immune system to eliminate the infection,
Table 3 Primary clinical manifestations and prognosis for dogs infected with the different species of Babesia found in Europe [4]
B. canis B. vogeli B. gibsoni B. microti-like sp.
History and
features
Young dogs, adult dogs, hunting
dogs/sheepdogs (German Shepherd
and Komondor) that live outdoors.
A greater number of cases is seen
in autumn, and spring
Puppies or adult/older dogs
with concomitant infectious
or non-infectious diseases
Common in fighting dogs
(Pit Bull Terrier and Tosa)
Young, adult dogs,
guard/hunting dogs
that live outdoors
Severity of disease Moderate to severe Mild to moderate Moderate to severe Moderate to severe
Clinical signs
and laboratory
abnormalities that
differ among
Babesia spp.
Petechiae, epistaxis, vomiting,
lymphadenomegaly, hypotension,
low T3 syndrome, mild to moderate
nonregenerative, normochromic,
and normocytic anaemia, regenerative
anaemia (less common), leukopenia
with neutropenia and/or lymphopenia,
hypoalbuminemia, elevation of liver
enzymes (ALT, AST, ALP), hypokalemia,
hyponatremia, and hyperchloremia,
hyperlactatemia, hyperphosphatemia,
hypertriglyceridemia, hypoglycemia,
prerenal and renal azotemia
Regenerative immune-
mediated hemolytic
anaemia, nonregenerative
anaemia, leukocytosis and
leukopenia
Lymph node enlargement,
enlargement of the spleen,
small-bowel diarrhea, weight
loss, protein-losing nephropathy,
PU/PD, and abdominal effusion.
Mild to severe regenerative
immune-mediated hemolytic
anaemia, neutropenia and
leukocytosis. Hypoalbuminemia,
azotemia and elevation of liver
enzymes (ALT, ALP)
Azotemia, proteinuria,
cylindruria and
hyperglobulinemia
Course of infection
related to disease
manifestation
Acute Acute and chronic Acute and chronic Acute and chronic?
Prognosis Good to poor Good Guarded to poor Guarded to poor
Reference [84, 89, 106, 131, 162–167] [84, 106, 162] [48, 102, 132, 168–171] [16, 35, 86, 172]
Common clinical signs and laboratory abnormalities among Babesia spp.: Fever, lethargy, anorexia, pale mucous membranes, weakness, bounding pulse, jaundice,
pigmenturia, mild to severe thrombocytopenia, mild to severe regenerative anaemia due to hemolysis, bilirubinemia, bilirubinuria, and haemoglobinuria
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which then establishes itself with more rigour when the
immune system is in abatement [4, 10].
Is light microscopy evaluation of a blood smear useful for
the diagnosis of canine babesiosis?
Blood smear examination is a useful diagnostic tool for
clinical babesiosis in dogs. Microscopy evaluation con-
tinues to be the easiest and most accessible diagnostic
test for most veterinarians. However, the sensitivity of
this method is lower than that of molecular diagnosis in
assisting the veterinarian in making a positive diagnosis and
is rather dependent on the species infecting the dog. The
two forms of Babesia, large (Fig. 2) and small (Figs. 3, 4),
can be distinguished using a blood smear. Although light
microscopy is highly specific and can be used to diagnose
the majority of sick dogs infected by the large forms of
Babesia (e.g. B. canis) [4, 84], it is less commonly detected
in B. vogeli infections [84]. For this infection, more sensitive
molecular PCR-based methods, are more appropriate [93].
The small piroplasms (B. gibsoni, B. microti-like sp.) are
hard to observe by light microscopy, which has relatively
poor to moderate sensitivity [35], and expertise is needed.
Blood smear observation should therefore be a “first step”
diagnostic tool, with negative blood smears reassessed by
PCR using blood or splenic tissue (Fig. 5). In addition, to
identify the species of piroplasm, morphological observa-
tion is insufficient, and molecular techniques such as PCR
and sequencing are necessary. Fresh blood is always recom-
mended for the smear. Additionally, observation of large
Babesia spp. in a capillary blood smear, such as that ob-
tained from the ear or nail, seems to be more easily accom-
plished thanks to the greater abundance of the parasite in
this type of sample [10, 88]. The limit of detection of para-
sites in a thin blood smear appear to be parasitemias of
0.5 % [88].
What serological techniques can be used to diagnose
babesiosis?
The serological tests that can be used are quantitative tech-
niques, such as indirect immunofluorescence (IFAT), or
enzyme-linked immunosorbent assay (ELISA). One of the
advantages of IFAT or ELISA is that these tests allow us to
determine the antibody levels and therefore establish
whether they are high or low. For this reason, it is import-
ant to send the samples to a laboratory that routinely uses
quantitative serological techniques and can provide a final
titre by IFAT or optical density by ELISA [42]. Rapid tech-
niques are not yet commercially available for the detection
of anti-Babesia antibodies for the clinical setting and will
offer only a “positive/negative” result, without providing an
antibody titre or level. Furthermore, quantitative techniques
Fig. 2 Photomicrograph showing a large-sized Babesia spp. (B. canis)
in canine erythrocytes. Scale-bar: 10 μm
Fig. 3 Photomicrograph of a small-sized Babesia spp. (B. gibsoni, arrow)
in canine erythrocytes. Scale-bar: 10 μm
Fig. 4 Photomicrograph of a small Babesia (B. microti-like sp., arrow)
in canine erythrocytes. Scale-bar: 10 μm
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are generally more sensitive and specific than rapid tech-
niques. Currently, no universal antigen has been developed
for screening using routine diagnostic serology against all
Babesia species that infect dogs. The most commonly used
antigen in practice and research is that for B. canis; B. gib-
soni [94, 95] and B. microti-like sp. [35] antigens are also
available, but information is scarce regarding these antigens.
In addition, the specificity and sensitivity of these tech-
niques are not well established [4]. Therefore, the scope for
diagnosis by serology is extremely limited and requires
further investigation. Nevertheless, false-negative PCR re-
sults have been reported in chronic babesiosis involving B.
gibsoni, attributed to parasite elimination from the circulat-
ing blood by the host. These data show that in the long
term (up to 420 days post-infection), an infection might be
revealed by serology only retrospectively [95].
How should we interpret a positive serological result for
Babesia spp.? Do serological cross-reactions exist among
different species of Babesia?
The interpretation of a positive result for Babesia when
using a serological technique is complicated by cross-
reactivity among the different species. In general terms,
there is significant cross-reactivity between different species
of Babesia, especially the more phylogenetically related
species. For example, cross-reactivity for large Babesia spp.
(B. canis and B. vogeli) can result in matching antibody
levels across species. Cross-reactions can also exist between
small Babesia spp. (B. gibsoni) and large species (B. canis)
[96] as well as between small Babesia spp. (B. gibsoni and
B. microti-like sp.) or between large Babesia spp. (B. canis,
B. vogeli and B. rossi) [28].
For this reason, a positive result would indicate expos-
ure to infection by Babesia but not precisely identify
which species. A positive serological result can also indi-
cate a past or current infection. Despite their infrequent
use in the clinical setting, molecular techniques would
provide a more informative diagnosis.
Could a seronegative dog be infected with Babesia spp.?
It is perfectly feasible for a dog to be seronegative and
infected with Babesia because infections by species such
as B. canis manifest acutely [4, 97]. Consequently, the three
to four-week lag in post-infection antibody production
would provide a serologically negative window. Therefore,
seroconversion could be used as a serological technique to
confirm acute infection by Babesia spp. In these cases, ini-
tial quantitative serology should be performed when the
DOGS WITH CLINICAL SIGNS AND CLINICOPATHOLOGICAL ABNORMALITIES COMPATIBLE WITH BABESIOSIS 
BLOOD SMEAR
EXAMINATION
FOR PARASITE 
VISUALIZATION
LARGE FORM
Babesia
SMALL FORM
Babesia
QUANTITATIVE 
SEROLOGY
(IFAT / ELISA)
PCR
1
2
43
Importance to distinguish 
large and small forms due 
to the fact that clinical 
management, treatment 
and prognosis are very 
1
Importance to use 
molecular techniques 
that  discriminate among 
Babesia species.
2
It indicates Babesia
exposure, but it does 
not discriminate among 
Babesia species.
3
a. Repeat after 4-8 
weeks for assessing 
seroconversion.
b. Rule out for other 
compatible diseases.
4
Fig. 5 Diagnostic algorithm for canine babesiosis
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patient first presents with clinical signs and/or labora-
tory abnormalities. Subsequently, quantitative serology
should be performed again after 4–8 weeks (see Fig. 5).
Medium to high positive antibody levels during the
convalescent phase (at least 3–4 weeks after infection)
can confirm infection by Babesia at the time of presen-
tation [35]. However, data are limited about the useful-
ness of seroconversion in canine Babesia infections.
Seroconversion is not commonly employed in clinical
practice.
Why is the amplification of DNA by PCR useful in the
diagnosis of babesiosis? What biological samples should
be chosen to perform a molecular diagnosis of Babesia
spp. infections?
In general terms, PCR is very useful in diagnosing
babesiosis. First, PCR detection is more sensitive than a
direct blood smear examination. Secondly, the detection
of DNA for a specific pathogen in a clinical setting can be
considered evidence of an active - and therefore ongoing -
infection. In addition, unlike direct detection by light
microscopy or serology, PCR allows a more reliable identi-
fication of the causative species infecting the dog [4].
Different molecular techniques allow the identification
and differentiation of the various species of Babesia.
These include semi-nested PCR [98], reverse line blot-
ting [99, 100], and PCR-restriction fragment length poly-
morphism analysis [101]. In addition, several genes are
commonly used to discriminate among Babesia species.
Typically, these include the nuclear ribosomal RNA
genes [7, 8] and the two internal transcribed spacers
(ITS1 and ITS2) [7]. These molecular techniques allow
us to refine our diagnosis to the species level and thus
provide a more accurate prognosis. Finally, PCR DNA
amplification can be a useful technique for monitoring
treatment [102].
Ideally, peripheral blood buffered with ethylenedi-
aminetetraacetic acid (EDTA) should be used to conduct
molecular analyses using PCR. Moreover, splenic tissue
can also be useful, although, as mentioned below, this
sample is not usually pursued because it involves a more
invasive procedure [4].
Are co-infections common in dogs infected with Babesia
spp.? What is the clinical importance of a co-infection for
the progression of disease?
Co-infections with Babesia spp. are not well documented
and are rarely reported in dogs. However, sequencing and
phylogenetic analyses suggest that the diversity of piro-
plasm species that co-infect dogs may be greater than pre-
viously thought [15, 21]. A study conducted with 120
Spanish dogs from Galicia and Asturias, all with clinical
signs compatible with babesiosis, demonstrated the pres-
ence of B. microti-like sp. in 75 dogs (62.5 %), with 15
dogs positive for other piroplasmid species (12 for B. canis
and three for B. gibsoni) [35]. Co-infection with other
agents was not detected, possibly indicating that co-
infection with other pathogens is not common [35]. More-
over, an interesting study found a high percentage of
co-infection with different strains of B. canis in dogs from
France [39]. In addition, co-infection with B. rossi and B.
vogeli and a triple infection with B. rossi, B. vogeli and
Ehrlichia canis have been reported in South African dogs
[103]. In contrast to the rare occurrence of co-infection
with different species of Babesia, it could be common in
endemic areas to find dogs co-infected with other patho-
gens such as Leishmania spp., Ehrlichia/Anaplasma spp.,
Hepatozoon spp. or Rickettsia conorii, depending on the
geographical area and the distribution of the competent
arthropod vectors [93, 104]. Additionally, it should be
noted that co-infection is of major clinical importance for
several reasons: it complicates diagnoses, exacerbates clin-
ical signs, reduces effectiveness of treatment, and can
worsen the prognosis [104].
What is the treatment of choice for Babesia infections?
Despite the large number of clinical cases and uncon-
trolled experimental studies, little robust scientific evi-
dence is available regarding the treatment of canine
babesiosis; Table 4 displays those currently used in dogs.
Imidocarb dipropionate is the treatment of choice for ca-
nine babesiosis caused by the large Babesia species. One
dose of 6.6 mg/kg intramuscularly (IM) or subcutaneously
(SC) is the recommended treatment. Although some au-
thors suggest an additional dose of imidocarb (separated
by 15 days for B. canis and B. vogeli infections), if the dog
does not respond adequately, it may be wiser to reconsider
the diagnosis. Moreover, this approach is not the treat-
ment of choice for small Babesia species (B. gibsoni and B.
microti-like sp.). The most frequently described side ef-
fects associated with this drug are pain at the injection site
and cholinergic signs (anorexia, hypersalivation, epiphora,
abdominal pain, vomiting and diarrhea), which generally
disappear quite quickly, although these latter effects can
be ameliorated by pre-medicating with atropine or glyco-
pyrrolate [12, 16, 105–107]. The toxic effect of an over-
dose of imidocarb dipriopionate is nephrotoxicity.
The combination of atovaquone and azithromycin is
the only treatment that has been proven to reduce para-
sitemia with B. gibsoni below the PCR limit of detection.
Atovaquone is an anti-parasitic drug that inhibits the
action of cytochrome b. The most commonly used
dose of atovaquone is 13.5 mg/kg, administered per os
(PO) every 8 h with fatty food (to maximise drug ab-
sorption) and in combination with azithromycin (at a
dose of 10 mg/kg PO) for ten days. This drug combin-
ation also seems to be effective in treating infections
with other small Babesia species like B. conradae [108]
Solano-Gallego et al. Parasites & Vectors  (2016) 9:336 Page 9 of 18
and is likely to be useful in treating B. microti-like sp. in-
fections. Nonetheless, it seems that in some cases, a
lower rate of success with atovaquone treatment is being
reported [102, 108–112]. Recently, the use of two IM
doses of buparvaquone at 5 mg/kg separated by 48 h has
demonstrated good clinical efficacy in dogs naturally in-
fected by B. microti-like sp. in Spain, with results super-
ior to those achieved with atovaquone [113].
Diminazene also seems effective against B. canis when
administered IM as a single dose of 3.5 mg/kg. However,
it does not have the same efficacy against B. gibsoni,
although it does reduce parasitemia, morbidity and mor-
tality. Side effects include neurological abnormalities,
which can be severe on overdose. Its use is currently
restricted to clinical cases that are refractory to other
treatments [114, 115], and it is not commonly used in
Europe. The use of combined clindamycin, diminazene
and imidocarb dipropionate may also be promising in
the treatment of B. gibsoni, as compared to the combin-
ation of atovaquone and azithromycin [116].
Antibiotics are not the treatment of choice for piro-
plasmosis. Nonetheless, doxycycline has been described
as lessening the severity of clinical signs and is associ-
ated with a reduction in morbidity and mortality for B.
canis and B. gibsoni infections [117, 118]. The most
commonly used dose is 10 mg/kg/day, administered PO
or (sporadically) intravenous (IV). In case of vomiting,
the recommendation is to split the dose into 5 mg/kg
given every 12 h [117]. Clindamycin has been used in
the treatment of B. gibsoni infection at a dose of 25 mg/
kg, administered PO every 12 h for 14 days and has been
shown to reduce clinical signs and laboratory abnormal-
ities [119]. It is important to remember that antibiotics
alone will not eliminate the infection. However, combi-
nations of different antibiotics have some efficacy in
treating dogs infected with B. gibsoni. Examples include
the combination of clindamycin (11 mg/kg every 12 h
PO), metronidazole (15 mg/kg every 12 h PO), and
doxycycline (5 mg/kg every 12 h PO); or enrofloxacin
(2.5 mg/kg every 12 h PO), metronidazole (5–15 mg/kg
every 12 h PO), and doxycycline (7–10 mg/kg every 12 h
PO) [118, 120]. In summary, because of the scarce scien-
tific evidence regarding the efficacy of antibiotics in
treating canine babesiosis, their use in these diseases
should be restricted.
Other treatments used with varying success to treat
babesiosis in dogs include quinuronium sulfate, trypan blue
solution and pentamidine; experimental treatments include
artesunate, plant extracts or tick peptides [114, 121–125].
Are there other supportive therapies that could be used
for babesiosis?
Supportive treatment is provided only to dogs admitted
for inpatient hospital-based care. Supportive care is
required for moderate to severe babesiosis. It is difficult
to characterise the proportion of cases that need sup-
portive treatment, which varies depending on the type of
Babesia species infecting the dog.
In dehydrated or hypovolemic dogs, the use of intra-
venous crystalloid fluid therapy is indicated, together
with the correction of electrolyte and acid–base abnor-
malities. Fluid therapy is also essential for maintenance
of blood volume and adequate end-organ perfusion, di-
uresis and prevention of red blood cell sludging in capil-
laries [10, 126]. In dogs with clinical signs associated
with anaemia, packed red blood cell transfusions should
be provided using pre-screened units; alternatively, syn-
thetic haemoglobin can be used. Dogs with disseminated
intravascular coagulation or coagulation disorders may
require plasma transfusions.
The use of immunosuppressant drugs in dogs with
immune-mediated haemolytic anaemia (IMHA) or
thrombocytopenia is controversial because these condi-
tions are always associated with infectious disease. If the
dog is stable and does not require hospitalisation, treat-
ment should be restricted to antiprotozoal agents; treat-
ment should not be initiated exclusively in relation to the
hematocrit or platelet value but rather based on the clinical
signs associated with the anaemia or thrombocytopenia.
Thus, occasionally, dogs with a hematocrit or platelet value
of less than 15 % or 40,000/μl, respectively, may manifest
good progress when treated with anti-babesial therapy
alone. If, despite antiprotozoal treatment, the dog has
moderate-to-severe clinical signs (or a high risk for them),
such as sudden collapse or spontaneous bleeding associ-
ated with IMHA (e.g. severe spherocytosis, autoagglutina-
tion, anti-erythrocyte antibodies or positive Coomb’s or
antinuclear antibody tests) and/or immune-mediated
thrombocytopenia (when platelets/μl are between 20,000
and 40,000), the use of 2 mg/kg/day of prednisone is
Table 4 Treatments used for infections with the various species of Babesia
Species Drugs Efficacy Dosage References
Babesia canis;
Babesia vogeli
Imidocarb dipropionate Good 6.6 mg/kg IM/SC once (can be repeated after 15 days) [105, 106]
Doxycycline Poor 10 mg/kg/day PO, 30 days [117]
Babesia microti-like sp. Imidocarb dipropionate Poor 6.6 mg/kg IM/SC once (can be repeated after 15 days) [12, 16, 105, 106]
Azithromycin + Atovaquone Good to moderate 10 mg/kg PO SID/10 d + 13.5 mg/kg PO TID/10 days [109, 113]
Azithromycin + Buparvaquone Good to moderate 10 mg/kg PO SID +5 mg/kg IM (repeat after 48 h) [113]
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recommended because prognosis is guarded to poor with
reported mortality rates of 28–70 % [127, 128]. However,
because no laboratory test or hematological parameter al-
lows the clinician to decide if the immunosuppressant
treatment is really necessary, in the majority of such cases,
a short course of treatment (ten days or less) is sufficient
for secondary IMHA or thrombocytopenia. Moreover, a
dose reduction could be implemented more rapidly than
usual when there are primary immune-mediated alter-
ations. Other immunosuppressant drugs have not shown
the same efficacy and are therefore not recommended.
Dogs previously treated with immunosuppressant drugs
over a sustained period of time before their treatment for
babesiosis do not have as good a clinical response and may
be predisposed to other infections and/or relapses [4, 10,
126]. Pulmonary thromboembolism is a common cause of
death in dogs with IMHA. Therefore, heparin, acetylsali-
cylic acid or clopridogrel might be used as a thrombopro-
phylaxis in dogs with IMHA [129].
Many other supportive therapies may be beneficial de-
pending on the clinical signs and/or laboratory abnormal-
ities, both those caused by the babesiosis directly and
those resulting from its treatment with antiprotozoal
agents. For example, anti-emetics should be used to coun-
ter vomiting, or oxygen therapy should be used when
there is respiratory distress [126, 130].
What is the expected clinical response following the
treatment of babesiosis?
The majority of dogs infected with large piroplasms
(B. canis and B. vogeli) improve clinically in days 1–7
after specific antiprotozoal treatment, although some
dogs will not respond until more than 15 days have
passed. Dogs infected with B. canis or B. vogeli will
generally manifest a complete recovery following their
treatment [90, 131]. In general, the clinical response is
good and more rapid (24–48 h) in dogs infected with
the large Babesia species than with small [4, 10]. How-
ever, a recent study reported a high mortality rate
(53 %, 8 out of 15) in dogs with babesiosis due to B.
canis during the first 24–48 h after clinical presenta-
tion and treatment [89]. In canine B. canis infections,
poor outcome and mortality are associated with moderate
anaemia, severe thrombocytopenia, mild to moderate
leukopenia, hyperlactatemia, moderately increased serum
phosphate and triglyceride concentrations and moderately
decreased total serum protein concentrations [89].
Some dogs infected with B. gibsoni and treated with
atovaquone and azithromycin do not show relapse of the
disease, and some remain PCR-negative for several years.
However, dogs that remain infected with B. gibsoni fol-
lowing treatment may present with a different clinical
picture. They may demonstrate a complete resolution of
anaemia, without clinical recurrence after stress (including
unrelated, disease-mediated), although occasionally, mild
thrombocytopenia or hypergammaglobulinemia persists.
For some dogs, clinical signs may disappear entirely, but
moderate anaemia, thrombocytopenia or hypergammaglo-
bulinemia will persist. Finally, in some other dogs, the
clinicopathological abnormalities may be resolved but can
reappear under stressful circumstances, which is especially
common in splenectomised dogs [102, 132].
In general, little information is available regarding the
clinical response of dogs infected with B. microti-like sp.
isolates. We would predict that their clinical progression
would be similar to that described for dogs infected with
B. gibsoni, likely because of the lack of any truly effective
treatment [16]. However, azotemia has been reported to
be the main cause of death for B. microti-like sp.-in-
fected dogs, with a mortality rate of 22 % [86], although
a pre-renal azotemia was not fully ruled out. Further-
more, a recent study carried out in the same area did
not yield the same findings [35]. In general, these dogs
have a very poor response to protocols using imido-
carb dipropionate [113]. Other therapeutic alternatives
are being considered, such as combinations of atova-
quone or buparvaquone with azithromycin. In the ma-
jority of dogs treated with these combinations, the trend
is towards a favourable initial clinical response [113],
but further follow-up studies are needed to evaluate
and compare relapse intervals for the various protocols.
Therefore, follow-up blood tests (complete blood count
and biochemical profile) are needed until hematocrit,
platelet concentration, and liver/kidney abnormalities
normalise. This is especially important in splenecto-
mised dogs or those dogs infected with B. gibsoni or
B. microti-like sp.
How do antibody levels evolve following treatment?
In general, antibody levels to Babesia spp. start decreas-
ing three weeks after initiating treatment and decrease
gradually thereafter over approximately 160 days [133].
Antibody results should always be interpreted with cau-
tion because elevated antibody levels have been reported
to routinely correlate with persistent infection [134]. For
some species of Babesia (e.g. B. gibsoni), it is normal to
find positive antibody levels following treatment, which
complicates the interpretation of positive results [111].
Taken together, these limitations, along with those already
described for serological analyses, make it inadvisable to
employ these techniques in disease follow-up.
Why is PCR useful after treatment?
PCR is a useful screening strategy given that many dogs
remain chronically infected with piroplasms. Their chron-
ically infected status predisposes these dogs to relapse or
to the maintenance of a chronically abnormal - and there-
fore injurious - clinical state. Under these circumstances,
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PCR can be used to establish whether the infection re-
mains or has been most likely cleared [4, 10].
PCR should be performed before interrupting treat-
ment and approximately 2 months after the completion
of treatment, especially when monitoring small Babesia
species. Additionally, because the sensitivity of PCR for
piroplasms in whole blood is less than 100 %, it may be
advisable to perform two consecutive PCR tests, sepa-
rated by at least 15 days [102, 111]. In addition, true
parasitic clearance can be rigorously demonstrated only
if PCR is performed using multiple tissue aspirates, such
as from the spleen, not just peripheral blood [10]. The
prohibitive cost of several splenic PCR tests tends to re-
strict its use to the research setting and to proof-of-
principle studies for therapeutic response.
Can canine babesiosis be cured?
Clinical cure and a good therapeutic response are much
more likely achieved for infections by large-sized Babesia
species than infections by the small-sized species, the
latter of which tend to be more refractory to conventional
treatments [4]. Several therapeutic protocols aimed at in-
fections caused by small Babesia species are used, al-
though parasitological cures are considered rare. The
persistence of B. gibsoni in dogs following treatment with
different protocols using clindamycin, metronidazole,
doxycycline, diminazene, imidocarb dipropionate, atova-
quone, and azithromycin is testament to the resilience of
this parasite [111, 112, 116, 119].
Can dogs be re-infected by Babesia spp.?
The same dog can be re-infected by identical Babesia spe-
cies or co-incidentally with a second species. Although the
clinical consequences of re-infections are not well defined,
in endemic regions, it is possible for dogs to be chronically
infected, in a premunition phase, without clinical conse-
quences; this phase may even be beneficial in terms of
protecting against future infection [133].
What tick control measures can be implemented to
prevent infection by Babesia spp. in dogs?
The predominant emphasis for the prevention of
babesiosis in dogs has been to focus on tick control.
However, this approach is complicated by the endophilic
nature of at least some of the ticks involved in its
transmission. The efficient transovarial transmission of
Babesia species in the tick implies that tick populations
in endemic areas can remain infected for a long time
and that dogs in contact with tick-infested areas will
routinely become re-infested and exponentially amplify
the tick population.
Tick prophylaxis should cover the entire period
during which ticks are active, depending on the level
of risk and lifestyle of the dogs. This prophylaxis may
consist of regular checking of the pet for ticks by the
owner and veterinarians and the regular use of acari-
cidal treatment.
Actions for the prevention of transmission of Babesia
infections should focus first and foremost on the following:
1. Any attached tick should be removed. Pet owners
should be aware of the importance of removing
ticks as soon as possible. A large variety of
purpose-designed tick removal tools are available
(these may be used for removal of ticks attached
to the skin; oil, alcohol or ether are not
recommended).
2. Dogs and cats travelling to regions with ticks and
endemic for babesiosis should also receive a regular
acaricidal treatment, particularly if this disease is not
endemic in their area.
3. Use acaricides with a residual action and water
resistance.
4. Engaging in tick control, applying a good
knowledge of tick seasonality. Ticks may be active
and parasitise dogs above an ambient average air
temperature of 12 °C. Below this temperature, it
becomes difficult for dogs to become infested,
which makes tick control much easier. Although
tick control is classically recommended between
spring and autumn, recent studies suggest that in
some areas, it should be applied all year around
[135, 136]; however, this recommendation should
be considered according to local conditions.
5. The removal of ticks from kennels is unfeasible;
therefore, the only and safe way to avoid the
colonisation of kennels and premises by ticks is
the protection of dogs, which are the only
“carriers” of ticks.
Principle active compounds considered to be effective
for the treatment and prevention of tick infestations in
dogs include a wide variety of ectoparasiticides, which
have shown different effects on ticks (repellency, anti-
feeding effect, disruption of attachment, expellency and/
or killing effect), so it is important to use suitable acari-
cides to kill the ticks as quickly as possible before patho-
gens are released. Considering babesiosis, it is even better
to prevent ticks from attaching (tick repellency sensu
stricto) [137].
A broad spectrum of acaricidal products are licensed
for use in dogs all over Europe. The different presenta-
tions include long-lasting efficacy collars (6–8 months),
spot-on pipettes (3–5 weeks), sprays (2–3 days) and the
new oral chewable tablets (1–3 months). These new oral
molecules are systemic acaricides; thus, ticks have to
attach to the host and start to feed to encounter the
active ingredients.
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In addition, reports are still rare regarding the efficacy
of acaricidal products to prevent Babesia infection.
These studies are mainly confined to B. canis transmis-
sion by D. reticulatus in dogs with percentages of pro-
tection that range between 88 and 100 % with a duration
from 4 weeks to 3 months (Table 5).
According to the registration of these compounds in
Europe, all of them can kill the already feeding tick
before the estimated 48 h of sporogony of Babesia spp.
in ticks [138], necessary for its transmission to dogs,
which starts when the tick begins to feed. Of note, dogs
exposed experimentally to D. reticulatus containing B.
canis tested positive for Babesia (PCR, blood smears)
after a 72-h infestation [139].
Different reports have documented the efficacy and
speed of killing ticks under natural infestations or after ex-
posure to experimental infestations when dogs are treated
with the different ectoparasiticides available. In general,
they are all useful, and the veterinarian should tailor the
best choice considering each individual dog (lifestyle, out-
door activities, working dogs, human–animal bond).
ESCCAP (European Scientific Counsel Companion Ani-
mal Parasites) have therapy tables in each country with the
whole portfolio available in Europe (www.esccap.org).
Are there vaccines available to prevent babesiosis in dogs?
A few commercially available vaccine options exist to pre-
vent Babesia infection in different animal species. For the
European market, a vaccine to protect dogs against B.
canis is available, called Pirodog® (Merial). This vaccine,
which comprises soluble parasite antigens obtained from
culture media supernatant [140–144], induces a partial
protection for dogs newly exposed to B. canis, which both
shortens and diminishes the severity of their clinical signs.
Vaccination does not prevent infection but appears to
block initiation of many of the pathological processes in-
volved in the disease; moreover, a lower parasitemia may
result. This vaccine can be administered from 5 months of
age and requires annual re-vaccination but does not
cross-protect against other Babesia species. Vaccines
against other Babesia species such as B. gibsoni are cur-
rently being developed [145, 146].
Are there other options available to prevent canine
babesiosis?
Although it is fair to say that the best way to control
babesiosis is to counter the vector itself, alternatives
other than vaccine development have been studied. One
possibility is a chemoprophylactic approach with a few
dated reports showing the effectiveness of the carbani-
lide derivative imidocarb dipropionate against B. canis
infection. In one instance, 6 mg/kg administered in three
doses, each separated by one week, resulted in no im-
provement [105]. However, a second study using a single
subcutaneous dose (again, 6 mg/kg) demonstrated pro-
tection for two weeks [147]. Doxycycline, used at a dose
of 5 mg/kg/day, reduces the severity of disease in dogs
infected experimentally with an extremely pathogenic
isolate of B. canis [117]. However, the chemoprophylac-
tic use of these drugs should be restricted to immuno-
suppressed dogs (primarily splenectomised dogs) with
an increased risk of exposure, including their residence
in endemic areas. For these patients, strict clinical and
parasitological follow-ups are needed using serological
diagnoses and supported with daily blood smears for at
least two weeks post-surgery [10]. The demonstration of
Babesia spp. transmission after blood transfusion, even
when using donor dogs that appear to be clinically
healthy [43], reinforces the need to test all prospective
canine blood donors with serology and PCR assays be-
fore transfusion [148]. Dogs positive by either or both
methods should not be used for blood donation.
Conclusions
Information on canine babesiosis in Europe has signifi-
cantly increased in the last few years. The present
Table 5 Acaricides with proven preventive efficacy against Babesia spp. transmission by D. reticulatus and R. sanguineus ticks in dogs
Principle active (Brand name, presentation - company) Percentage of protection of B. canis
infection (time period of evaluation)
Acaricide efficacy against D. reticulatus
in % (time period of evaluation)
Reference
Afoxolaner (NexGard®, chewable tablets - MERIAL) 100 (56 days) 99 (4 weeks) [173]
Fipronil + Permethrin (Frontline Tri-Act®, Spot
on - MERIAL)
94.3 (4 weeks) 98.3 (28 days) [174]
Fluralaner (Bravecto®, chewable tablets - MSD) 100 (12 weeks) 99.2 (86 days) [175]
Flumethrin + Imidacloprid (Seresto® Collar - BAYER) 100 (4 weeks) 96.0 (48 h), 100 (4 days) [176]
Percentage of protection of B. vogeli
infection (time period of evaluation)
Acaricide efficacy against R. sanguineus
in % (time period of evaluation)
Flumethrin + Imidacloprid (Seresto® Collar - BAYER) 100 (1 year) 99.7 (48 h) [177]
Imidacloprid + Permethrin (Advantix®, spot on - BAYER) 88.3–94.4 % (12 months)a 95–100 [178, 179]
aThe molecular diagnosis was Babesia spp. Identification to the species level was not carried out. However, the studies were performed in the south of Italy, so
that the species of Babesia infecting dogs was most likely B. vogeli
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guidelines aim to answer common questions about the
aetiology, epidemiology and transmission routes, clin-
ical signs, laboratory findings, diagnosis, treatment and
prophylaxis of infections caused by Babesia spp. We
also hope that this review will contribute to the under-
standing of the current status of these diseases in
Europe. It is important to highlight that canine
babesiosis represents a group of diseases and that many
species can infect dogs in Europe. Therefore, accurate
detection and species recognition is crucial for selecting
the most appropriate treatment and determining the
most accurate prognosis.
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